This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Talkspace Shares Decline Despite Partnership With Wisdo Health
by Zacks Equity Research
TALK collaborates with Wisdo Health to enhance mental health support for seniors, addressing loneliness and improving access to care for the 65+ community.
ADUSPositive Net Change RDNTPositive Net Change AVAHNegative Net Change TALKPositive Net Change
medical medical-devices
Illumina's Q3 Earnings Coming Up: Time to Buy, Sell or Hold the Stock?
by Moumi Mondal
In the third quarter of 2024, ILMN is likely to have benefited from the significant step-up in consumables with growing customer activity on NovaSeq X.
ILMNPositive Net Change QGENPositive Net Change PACBPositive Net Change
dna-sequencing earnings-preview genomics medical medical-devices
Precision BioSciences to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
DTIL is expected to provide updates on its in vivo gene editing programs in the third-quarter earnings release, given the absence of a marketed product.
REGNPositive Net Change PFENegative Net Change NVONegative Net Change DTILPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
LifeMD Shares Decline Even After the Launch of Testosterone Therapy
by Zacks Equity Research
LFMD expands its men's health services with TestoRx, offering convenient testosterone therapy and alternative treatments for low testosterone via telehealth.
ADUSPositive Net Change RDNTPositive Net Change LFMDPositive Net Change AVAHNegative Net Change
medical medical-devices
LH Beats on Q3 Earnings, Raises Revenue Guidance Midpoint, Stock Gains
by Zacks Equity Research
Labcorp beats on earnings and revenues in the third quarter, entering the fourth half of 2024 with robust momentum.
LHNegative Net Change PAHCPositive Net Change HQYPositive Net Change VCYTPositive Net Change
earnings medical
CTLT Stock Falls as Potential Hindrance to NVO Buyout Deal Increases
by Zacks Equity Research
Catalent stock faces uncertainty as several pharma companies voice concern about potential limited competition following the acquisition, especially in weight-loss drug manufacturing.
RHHBYPositive Net Change NVONegative Net Change LLYNegative Net Change CTLTPositive Net Change
medical medical-devices
West Pharmaceutical Stock Gains on Q3 Earnings Beat & Raised Guidance
by Zacks Equity Research
WST's third-quarter results reflect a recovery in the Proprietary Products segment following elevated customer destocking, hurting sales in the second quarter.
ANGONegative Net Change WSTPositive Net Change GMEDPositive Net Change AVNSPositive Net Change
earnings medical medical-devices
5 Top Dividend Stocks That Promise Substantial Growth
by Sweta Killa
Leidos Holdings, NetApp, ResMed, Trane Technologies and Travelers could be compelling picks for investors looking for dividend stocks.
NTAPPositive Net Change TRVNegative Net Change RMDPositive Net Change LDOSNegative Net Change TTPositive Net Change
aerospace business-services insurance medical semiconductor
Best Momentum Stocks to Buy for October 24th
by Zacks Equity Research
FOLD, CLPR and HROW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 24, 2024.
FOLDPositive Net Change CLPRNegative Net Change HROWPositive Net Change
medical
Summit Therapeutics Stock: Sell or Hold Before Q3 Earnings?
by Zacks Equity Research
Devoid of any marketed drug in its portfolio, investors will likely focus on SMMT's pipeline updates when it reports third-quarter results this month.
MRKNegative Net Change SMMTPositive Net Change TILNegative Net Change BNTXNegative Net Change
biotechs medical pharmaceuticals
VKTX Beats on Q3 Earnings, Stock Up on Obesity Pipeline Advancements
by Zacks Equity Research
Viking Therapeutics' third-quarter earnings outpace estimates. The company plans to start a mid-stage study on its obesity pill before 2024-end.
FOLDPositive Net Change FATEPositive Net Change VKTXPositive Net Change CSTLNegative Net Change
biotechs medical pharmaceuticals
ALGN Q3 Earnings Top Estimates, Revenues Miss, Stock Falls
by Zacks Equity Research
Align Technology reports third-quarter 2024 revenue growth. This can be mostly attributed to a robust performance by the Imaging Systems & CAD/CAM Services business segment.
ISRGPositive Net Change ALGNPositive Net Change ADUSPositive Net Change HQYPositive Net Change
earnings medical
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright
by Ekta Bagri
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector.
EXELPositive Net Change FOLDPositive Net Change BPMCPositive Net Change CRSPPositive Net Change VRNAPositive Net Change
biotechnology biotechs crispr medical pharmaceuticals
New Strong Buy Stocks for October 24th
by Zacks Equity Research
CLPR, HROW, FOLD, GTLB and TCOM have been added to the Zacks Rank #1 (Strong Buy) List on October 24, 2024.
FOLDPositive Net Change CLPRNegative Net Change HROWPositive Net Change TCOMPositive Net Change GTLBPositive Net Change
computers medical travel-leisure
Zacks Industry Outlook Highlights Quest Diagnostics, Encompass Health, Amedisys and Addus HomeCare
by Zacks Equity Research
Quest Diagnostics, Encompass Health, Amedisys and Addus HomeCare have been highlighted in this Industry Outlook article.
AMEDPositive Net Change DGXPositive Net Change ADUSPositive Net Change EHCNegative Net Change
medical
Starboard Slams Pfizer for R&D Inefficiencies, Overpaid Acquisitions
by Zacks Equity Research
Starboard calls out PFE's board of directors to take action against the latter's management for not earning sustainable revenue returns on R&D and M&A.
ALNYPositive Net Change PFENegative Net Change ANIPPositive Net Change CSTLNegative Net Change
biotechs medical pharmaceuticals vaccines
BSX Q3 Earnings Top, Stock Down in Premarket as Operating Margin Falls
by Zacks Equity Research
Boston Scientific registers year-over-year improvement in sales, indicating solid market share gains in legacy businesses despite macroeconomic odds.
BSXNegative Net Change BAXPositive Net Change MASIPositive Net Change GMEDPositive Net Change
earnings medical medical-devices
ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE
by Zacks Equity Research
AngioDynamics announces the receipt of CPT Category I code for IRE technology.
ANGONegative Net Change DGXPositive Net Change ADUSPositive Net Change RDNTPositive Net Change
medical medical-devices
Reasons to Retain Ecolab Stock in Your Portfolio for Now
by Zacks Equity Research
ECL's focus on cost-efficiency programs raises optimism about the stock.
ECLNegative Net Change DGXPositive Net Change ADUSPositive Net Change RDNTPositive Net Change
medical medical-devices
Growing Biosimilars Business Supports ABT Stock, Macro Issues Hurt
by Zacks Equity Research
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
ABTPositive Net Change BSXNegative Net Change BAXPositive Net Change MASIPositive Net Change
medical medical-devices
Should You Buy or Sell Centene Stock Before Q3 Earnings Report?
by Zacks Equity Research
CNC's third-quarter earnings are likely to have been affected by lower premiums and rising medical costs.
HUMPositive Net Change MOHPositive Net Change CNCPositive Net Change
earnings insurance medical
EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down
by Zacks Equity Research
Editas stock falls on a decision to seek a partner for its lead gene-therapy candidate, reni-cell, for SCD and TDT and focus resources on in vivo pipeline development.
VRTXNegative Net Change ANIPPositive Net Change FATEPositive Net Change EDITPositive Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
4 Stocks to Buy in an Evolving Outpatient Home Health Industry
by Debanjana Dey
Dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, EHC, AMED and ADUS are well-poised to gain.
DGXPositive Net Change AMEDPositive Net Change ADUSPositive Net Change EHCNegative Net Change
medical medical-devices
Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Neurocrine Biosciences (NBIX) stock based on the movements in the options market lately.
NBIXPositive Net Change
medical
Revvity Shares Decline Despite Launch of Transcribe AI Solution
by Zacks Equity Research
RVTY introduces Transcribe AI that digitizes handwritten test request forms, improving workflow speed and reducing manual data entry errors.
DGXPositive Net Change ADUSPositive Net Change RDNTPositive Net Change RVTYPositive Net Change
medical medical-devices